John Wm Martens

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. pmc DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERα-positive breast cancer cells
    Marleen Ansems
    Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB, Nijmegen, The Netherlands
    Breast Cancer Res Treat 149:693-703. 2015
  2. pmc Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers
    Anieta M Sieuwerts
    Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Dr Molewaterplein 50, 3015 GE, Rotterdam, Netherlands
    Horm Cancer 5:405-13. 2014
  3. pmc High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes
    Muhammad Riaz
    Erasmus University Medical Center Daniel den Hoed Cancer Center, Department of Medical Oncology and Cancer Genomics Center, Rotterdam, The Netherlands
    Breast Cancer Res 14:R123. 2012
  4. pmc Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer
    Jack X Yu
    Veridex LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
    BMC Cancer 7:182. 2007
  5. pmc CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients
    Dimo Dietrich
    Epigenomics AG, Berlin, Germany
    BMC Cancer 10:247. 2010
  6. pmc Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study
    Anieta M Sieuwerts
    Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Erasmus Medical Center, Rotterdam, GE, The Netherlands
    Breast Cancer Res 12:R103. 2010

Collaborators

  • Anieta M Sieuwerts
  • John A Foekens
  • Paul N Span
  • Muhammad Riaz
  • Marleen Ansems
  • Marcel Smid
  • Dimo Dietrich
  • Jack X Yu
  • Annemarie M A de Graaf
  • Maaike W G Looman
  • Gosse J Adema
  • Jonas Nørskov Søndergaard
  • Malou Zuidscherwoude
  • Vanja de Weerd
  • Manuel Krispin
  • Anne Fassbender
  • Jörn Dietrich
  • Nadia Harbeck
  • Vincent Vuaroqueaux
  • Serenella Eppenberger-Castori
  • Frederique Spyratos
  • Jörn Lewin
  • Ralf Lesche
  • Manfred Schmitt
  • Yixin Wang
  • Jan G M Klijn
  • Yi Zhang

Detail Information

Publications6

  1. pmc DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERα-positive breast cancer cells
    Marleen Ansems
    Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB, Nijmegen, The Netherlands
    Breast Cancer Res Treat 149:693-703. 2015
    ..Collectively, these data show that DC-SCRIPT acts as a novel regulator of CDKN2B and induces cell cycle arrest in ESR1-positive breast cancer cells. ..
  2. pmc Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers
    Anieta M Sieuwerts
    Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Dr Molewaterplein 50, 3015 GE, Rotterdam, Netherlands
    Horm Cancer 5:405-13. 2014
    ..42, P = 0.0079). APOBEC3B is a marker of pure prognosis and poor outcomes for ER + breast cancer, which strongly suggests that genetic aberrations induced by APOBEC3B contribute to breast cancer progression. ..
  3. pmc High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes
    Muhammad Riaz
    Erasmus University Medical Center Daniel den Hoed Cancer Center, Department of Medical Oncology and Cancer Genomics Center, Rotterdam, The Netherlands
    Breast Cancer Res 14:R123. 2012
    ..The biological associations suggest an involvement of the tumor microenvironment in TWIST1's adverse role in breast cancer...
  4. pmc Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer
    Jack X Yu
    Veridex LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
    BMC Cancer 7:182. 2007
    ..Published prognostic gene signatures in breast cancer have few genes in common. Here we provide a rationale for this observation by studying the prognostic power and the underlying biological pathways of different gene signatures...
  5. pmc CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients
    Dimo Dietrich
    Epigenomics AG, Berlin, Germany
    BMC Cancer 10:247. 2010
    ..In this study, the DNA methylation status of 202 candidate loci was screened to identify those loci that may predict outcome in LNP/estrogen receptor-positive (ER+) breast cancer patients with adjuvant anthracycline-based chemotherapy...
  6. pmc Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study
    Anieta M Sieuwerts
    Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Erasmus Medical Center, Rotterdam, GE, The Netherlands
    Breast Cancer Res 12:R103. 2010
    ....